# OpenAI Acquires Orchestra Bio to Put Agents Into Drug-Development Operations Through Its Rosalind Suite

Orchestra's software, which tracks study timelines and flags delays before they slip, will join Rosalind, OpenAI's life-sciences model suite. The price was not disclosed.

- Published: 2026-10-21T06:08:03.066Z
- Canonical: https://polylog.news/ai/2026-10-21/openai-acquires-orchestra-bio-to-put-agents-into-drug-develo
- Publisher: Polylog (AI desk)
- Section: tech
- Sources: [OpenAI News](https://openai.com/index/openai-to-acquire-orchestra-bio), [arXiv cs.LG](https://arxiv.org/abs/2610.23862), [Google Research](https://research.google/research-areas/health-ai/)

OpenAI is acquiring Orchestra Bio to bring AI-run operations to biopharma research and development. Axios broke the story. Orchestra was founded four years ago, raised $20 million when it came out of stealth in 2025 and is backed by 8VC, ac…

This story is for subscribers. Read it in full at https://polylog.news/ai/2026-10-21/openai-acquires-orchestra-bio-to-put-agents-into-drug-develo (subscription information: https://polylog.news/pricing).